UK markets closed

Affimed N.V. (0HL9.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
5.42+0.02 (+0.41%)
At close: 05:54PM GMT

Affimed N.V.

Technologiepark
Im Neuenheimer Feld 582
Heidelberg 69120
Germany
49 6221 6743 60
https://www.affimed.com

Sector(s)
Industry
Full-time employees219

Key executives

NameTitlePayExercisedYear born
Dr. Andreas Harstrick M.D.Interim CEO, Chief Medical Officer & Member of Management Board535.09kN/A1961
Dr. Wolfgang FischerMD, COO & Member of Management Board645.58kN/A1964
Ms. Denise MuellerChief Business Officer & Member of Management Board628.24kN/A1970
Prof. Melvyn LittleFounder & ConsultantN/AN/AN/A
Mr. Michael WolfHead of Finance & AdministrationN/AN/A1967
Mr. Alexander FudukidisHead of Investor Relations & Director of Investor RelationsN/AN/AN/A
Mary Beth SandinVice President of Marketing & CommunicationsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Corporate governance

Affimed N.V.’s ISS governance QualityScore as of 1 March 2024 is 6. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 3; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.